Richard G. Stock, MD, Author at Grand Rounds in Urology

Richard G. Stock, MD

Icahn School of Medicine at Mount Sinai

New York, New York

Richard G. Stock, MD, is a Professor of Radiation Oncology at Mount Sinai in New York, New York. Dr. Stock’s clinical interests include cancers of the bladder, prostate, testis, and bone. His research focuses on prostate cancer and prostate brachytherapy. Dr. Stock is best known for establishing a comprehensive prostate cancer database with a corresponding IRB approved protocol to track treatment outcomes following prostate cancer therapies.

Dr. Stock earned his medical degree and an internship in Internal Medicine from Mount Sinai. He then completed a residency in Internal Medicine at the Beth Israel Medical Center in New York, New York. Dr. Stock then completed a residency in Radiation Oncology at the Memorial Sloan Kettering Cancer Center in New York, New York.

Dr. Stock has served on the board of American College of Radiology Testing and the American Brachytherapy Society. He also served as a guest editor of a special Brachytherapy issue of Techniques in Urology. Dr. Stock has authored and co-authored over 140 publications and has contributed substantially to the understanding of prostate brachytherapy. Dr. Stock is also a co-investigator on Department of Defense, American Cancer Society, and NIH RO1 grants to study the relationship between genetic mutations and radiation side effects for patients undergoing radiation for prostate cancer. In a recent publication in the International Journal of Radiation Oncology Biology Physics, Dr. Stock ranked among the top 4% of academic Radiation Oncologists in terms of the h-factor, a surrogate score for research productivity.

Talks by Richard G. Stock, MD

Hydrogel Rectal Spacer: Radiopaque vs. Non-radiopaque

Richard G. Stock, MD | Mar 2025

Richard G. Stock, MD, explores the role of rectal spacers in reducing gastrointestinal toxicity during prostate cancer radiotherapy.

Adaptive Radiotherapy

Richard G. Stock, MD | Feb 2025

In this 23-minute presentation, Richard D. Stock, MD, explores integrating artificial intelligence in radiation oncology, focusing on adaptive radiation therapy (ART). Three categories of ART—offline, online, and real-time—are detailed, explaining their respective timelines, imaging technologies, and resource requirements. The discussion critically evaluates ART in prostate cancer, where anatomical shifts due to bladder or rectal changes can influence treatment accuracy.

Examples of imaging technologies like MRI and PET scans are discussed for their contributions to ART’s precision and potential to adapt treatment based on tumor shrinkage or biological response. Comparative studies from the Netherlands and other institutions demonstrate ART’s ability to refine target margins, decrease normal tissue exposure, and predict patient outcomes more accurately.

As ART shows promise in improving treatment precision, Dr. Stock emphasizes its potential for advancing radiation oncology, driven by technological innovation and ongoing research.

Panel Discussion: Didactic Session 4: Advances in Radiotherapy

Steven J. Frank, MD, FACR, FABS, FASTRO, Richard G. Stock, MD, Nelson N. Stone, MD and Juanita M. Crook, MD, FRCPC | Aug 2024

Steven J. Frank, MD, FACR, FABS, FASTRO; Richard G. Stock, MD; Nelson N. Stone, MD; Juanita M. Crook, MD, FRCPC

Panel Discussion: Didactic Session 2: Radioprotection

Leonard S. Marks, MD, Richard G. Stock, MD and Peter F. Orio III, DO, MS | Aug 2024

Peter F. Orio III, DO, MS; Leonard S. Marks, MD; Richard G. Stock, MD

Adjuvant-Salvage Radiotherapy Following Prostatectomy

Richard G. Stock, MD | Oct 2023

Richard G. Stock, MD analyzes adjuvant and salvage radiotherapy following prostatectomy in prostate cancer patients with high-risk features or biochemical recurrence post-surgery. Adjuvant radiotherapy is administered shortly after prostatectomy in patients with adverse pathological features, such as positive surgical margins or seminal vesicle invasion, aiming to eradicate microscopic residual disease. Salvage radiotherapy is employed in response to a rising prostate-specific antigen (PSA) level indicating biochemical recurrence after an initial period of undetectable PSA post-surgery.
Dr. Stock reviews pivotal clinical trials and studies, including the SWOG 8794, EORTC 22911, and ARO 96-02 trials, which have demonstrated the efficacy of adjuvant radiotherapy in improving biochemical progression-free survival and overall survival in patients with high-risk features. He highlights the long-term benefits of early intervention with radiotherapy, emphasizing its potential to prevent metastatic progression.